These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32461019)

  • 1. A novel method for preparing Eligulstat through chiral resolution.
    Du J; Chu W; Zhang M; Ma C; Feng W
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127209. PubMed ID: 32461019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliglustat: first global approval.
    Poole RM
    Drugs; 2014 Oct; 74(15):1829-36. PubMed ID: 25239269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
    Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
    Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
    Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
    JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
    Bennett LL; Turcotte K
    Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
    Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
    Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise asymmetric synthesis of new enantiomeric
    Castellan T; Garcia V; Rodriguez F; Fabing I; Shchukin Y; Tran ML; Ballereau S; Levade T; Génisson Y; Dehoux C
    Org Biomol Chem; 2020 Oct; 18(39):7852-7861. PubMed ID: 32975266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
    Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
    Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
    Cox TM
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
    Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
    Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
    Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD
    ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of Glucosylceramide Synthase.
    Shayman JA; Hinkovska-Galcheva V; Shu L
    Methods Mol Biol; 2023; 2613():271-288. PubMed ID: 36587085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
    Shayman JA
    Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 Gaucher disease (CYP2D6-eliglustat).
    Becquemont L
    Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
    Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
    Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
    Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
    Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
    Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
    Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy.
    Pavlova EV; Archer J; Wang S; Dekker N; Aerts JM; Karlsson S; Cox TM
    J Pathol; 2015 Jan; 235(1):113-24. PubMed ID: 25256118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
    Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.